UCB S.A.
UCB
Ранг среди акций
#528
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Цена акции
$242.09
Последняя синхронизация: 2026-10-16
Рыночная капитализация
$46.16B
Изменение (1 день)
-0.92%
Изменение (1 год)
-16.48%
Страна
BE
Торговля UCB S.A. (UCB)
Категория
Healthcare
Операционная маржа для UCB S.A. (UCB)
Операционная маржа на October 2026 TTM: 31.23%
Согласно последним финансовым отчетам и цене акций UCB S.A., текущая операционная маржа (TTM) составляет 31.23%. В конце 2023 она составила 11.50%.
История операционной маржи UCB S.A. с 2002 по 2026
Операционная маржа на конец каждого года
| Год | Операционная маржа | Изменить |
|---|---|---|
| 2026 (TTM) | 31.23% | 45.12% |
| 2024 | 21.52% | 87.13% |
| 2023 | 11.50% | 58.62% |
| 2022 | 7.25% | -63.48% |
| 2021 | 19.85% | 8.65% |
| 2020 | 18.27% | -17.18% |
| 2019 | 22.06% | -8.12% |
| 2018 | 24.01% | -0.08% |
| 2017 | 24.03% | 25.22% |
| 2016 | 19.19% | 28.88% |
| 2015 | 14.89% | 31.07% |
| 2014 | 11.36% | 16.27% |
| 2013 | 9.77% | -13.08% |
| 2012 | 11.24% | 6.04% |
| 2011 | 10.60% | 67.19% |
| 2010 | 6.34% | -76.40% |
| 2009 | 26.86% | 755.41% |
| 2008 | 3.14% | -66.91% |
| 2007 | 9.49% | -58.06% |
| 2006 | 22.63% | 45.53% |
| 2005 | 15.55% | 13.50% |
| 2004 | 13.70% | -6.29% |
| 2003 | 14.62% | 64.09% |
| 2002 | 8.91% | 0.00% |
Операционная маржа для аналогичных компаний или конкурентов
| Компания | Операционная маржа | Разница в операционной марже | Страна |
|---|---|---|---|
| 38.59% | -98.76% |
US
|
|
| -149.01% | -104.77% |
US
|
|
| 25.57% | -99.18% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.08% |
NL
|
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.